Long-term effects of bilateral oophorectomy on brain aging: Unanswered questions from the Mayo Clinic cohorts study of oophorectomy and aging

Women's Health

Volumn 5, Issue 1, 2009, Pages 39-48

  Rocca, Walter A ^a   Shuster, Lynne T ^a   Grossardt, Brandon R ^a   Maraganore, Demetrius M ^a   Gostout, Bobbie S ^a   Geda, Yonas E ^a   Melton III, L Joseph ^a  

^a MAYO CLINIC   (United States)

Author keywords

Anxiety; Dementia; Depression; Estrogen; Gonadotropins; Menopause; Oophorectomy; Parkinsonism; Progesterone; Testosterone

Indexed keywords

APOLIPOPROTEIN E; ESTROGEN; ESTROGEN RECEPTOR; FOLLITROPIN; GONADORELIN ANTAGONIST; LUTEINIZING HORMONE; PLACEBO; PROGESTERONE; TESTOSTERONE;

ADENOMYOSIS; AGING; ALZHEIMER DISEASE; ANXIETY; ARTICLE; CLINICAL TRIAL; COGNITIVE DEFECT; DEMENTIA; DEPRESSION; ENDOMETRIOSIS; ESTROGEN DEFICIENCY; FOLLITROPIN RELEASE; GENETIC PREDISPOSITION; GENETIC RISK; GENETIC VARIABILITY; GENOTYPE; GONADOTROPIN RELEASE; HORMONE SUBSTITUTION; HUMAN; HYPOTHALAMUS HYPOPHYSIS GONAD SYSTEM; HYSTERECTOMY; LUTEINIZING HORMONE RELEASE; MENORRHAGIA; NERVE FIBER GROWTH; NERVE REGENERATION; NEUROLOGIC DISEASE; NEUROPROTECTION; NONHUMAN; OVARIECTOMY; OVARY CYST; PARKINSONISM; PREMENOPAUSE; RISK FACTOR; SINGLE NUCLEOTIDE POLYMORPHISM; UTERUS MYOMA;

AGING; ANXIETY; BRAIN DISEASES; COHORT STUDIES; CONFOUNDING FACTORS (EPIDEMIOLOGY); DEPRESSION; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HORMONES; HUMANS; MINNESOTA; NEURODEGENERATIVE DISEASES; OVARIECTOMY; PREMENOPAUSE; QUESTIONNAIRES; RISK FACTORS;

EID: 59449088839     PISSN: 17455057     EISSN: 17455065     Source Type: Journal    
DOI: 10.2217/17455057.5.1.39     Document Type: Article

References (76)

1. Parker WH, Broder MS, Liu Z, Shoupe D, Farquhar C, Berek JS: Ovarian conservation at the time of hysterectomy for benign disease. Obstet. Gynecol. 106, 219-226 (2005).
2. Keshavarz H, Hillis SD, Kieke BA, Marchbanks PA: Hysterectomy surveillance - United States, 1994-1999. MMWR Surveill. Summ. 51, 1-8 (2002).
3. Rocca WA, Grossardt BR, de Andrade M, Malkasian GD, Melton LJ 3rd: Survival patterns after oophorectomy in premenopausal women: a population-based cohort study. Lancet Oncol. 7, 821-828 (2006).
4. Shoupe D, Parker WH, Broder MS, Liu Z, Farquhar C, Berek JS: Elective oophorectomy for benign gynecological disorders. Menopause 580-585 (2007).
5. Parker WH, Broder MS, Liu Z, Shoupe D, Farquhar C, Berek JS: Ovarian conservation at the time of hysterectomy for benign disease. Clin. Obstet. Gynecol. 50, 354-361 (2007).
6. ACOG: ACOG Practice Bulletin No. 89. Elective and risk-reducing salpingo-oophorectomy. Obstet. Gynecol. 111, 231-241 (2008).
7. Shuster LT, Gostout BS, Grossardt BR, Rocca WA: Prophylactic oophorectomy in premenopausal women and long-term health. Menopause Int. 14, 111-116 (2008).
8. Melton LJ 3rd, Bergstralh EJ, Malkasian GD, O'Fallon WM: Bilateral oophorectomy trends in Olmsted County, Minnesota, 1950-1987. Epidemiology 2, 149-152 (1991).
9. Rivera CM, Grossardt BR, Rhodes DJ et al.: Increased cardiovascular mortality following early bilateral oophorectomy. Menopause DOI: 10.1097/gme.0b013e31818888f7 (2008)
10. Rocca WA, Bower JH, Maraganore DM et al.: Increased risk of cognitive impairment or dementia in women who underwent oophorectomy before menopause. Neurology 69, 1074-1083 (2007).
11. Rocca WA, Bower JH, Maraganore DM et al.: Increased risk of parkinsonism in women who underwent oophorectomy before menopause. Neurology 70, 200-209 (2008).
12. Rocca WA, Grossardt BR, Maraganore DM: The long-term effects of oophorectomy on cognitive and motor aging are age dependent. Neurodegener. Dis. 5, 257-260 (2008).
13. Rocca WA, Grossardt BR, Geda YE et al.: Long-term risk of depressive and anxiety symptoms following early bilateral oophorectomy. Menopause 15(6), 1050-1059 (2008).
14. Hughes CL Jr, Wall LL, Creasman WT: Reproductive hormone levels in gynecologic oncology patients undergoing surgical castration after spontaneous menopause. Gynecol. Oncol. 40, 42-45 (1991).
15. Laughlin GA, Barrett-Connor E, Kritz-Silverstein D, von Mühlen DG: Hysterectomy, oophorectomy, and endogenous sex hormone levels in older women: the Rancho Bernardo Study. J. Clin. Endocrinol. Metab. 85, 645-651 (2000).
16. Simpson ER, Davis SR: Minireview: aromatase and the regulation of estrogen biosynthesis - some new perspectives. Endocrinology 142, 4589-4594 (2001).
17. Simpson ER: Aromatization of androgens in women: current concepts and findings. Fertil. Steril. 77, S6-S10 (2002).
18. Iivonen S, Corder E, Lehtovirta M et al.: Polymorphisms in the CYP19 gene confer increased risk for Alzheimer disease. Neurology 62, 1170-1176 (2004).
19. Armstrong K, Schwartz JS, Randall T, Rubin SC, Weber B: Hormone replacement therapy and life expectancy after prophylactic oophorectomy in women with BRCA1/2 mutations: a decision ana lysis. J. Clin. Oncol. 22, 1045-1054 (2004).
20. Burger HG, Hale GE, Dennerstein L, Robertson DM: Cycle and hormone changes during perimenopause: the key role of ovarian function. Menopause 15, 603-612 (2008).
21. Prior JC: Ovarian aging and the perimenopausal transition: the paradox of endogenous ovarian hyperstimulation. Endocrine 26, 297-300 (2005).
22. Morrison JH, Brinton RD, Schmidt PJ, Gore AC: Estrogen, menopause, and the aging brain: how basic neuroscience can inform hormone therapy in women. J. Neurosci. 26, 10332-10348 (2006).
23. Gibbs RG: Long-term treatment with estrogen and progesterone enhances acquisition of a spatial memory task by ovariectomized aged rats. Neurobiol. Aging 21, 107-116 (2000).
24. Webber KM, Casadesus G, Marlatt MW et al.: Estrogen bows to a new master: the role of gonadotropins in Alzheimer pathogenesis. Ann. NY Acad. Sci. 1052, 201-209 (2005).
25. Singh M: Progesterone-induced neuroprotection. Endocrine 29, 271-274 (2006).
26. Singh M, Sumien N, Kyser C, Simpkins JW: Estrogens and progesterone as neuroprotectants: what animal models teach us. Front. Biosci. 13, 1083-1089 (2008).
27. Snieder H, MacGregor AJ, Spector TD: Genes control the cessation of a woman's reproductive life: a twin study of hysterectomy and age at menopause. J. Clin. Endocrinol. Metab. 83, 1875-1880 (1998).
28. Weel AE, Uitterlinden AG, Westendorp IC et al.: Estrogen receptor polymorphism predicts the onset of natural and surgical menopause. J. Clin. Endocrinol. Metab. 84, 3146-3150 (1999).
29. Cramer DW, Petterson KS, Barbieri RL, Huhtaniemi IT: Reproductive hormones, cancers, and conditions in relation to a common genetic variant of luteinizing hormone. Hum. Reprod. 15, 2103-2107 (2000).
30. Di W, Guo SW: The search for genetic variants predisposing women to endometriosis. Curr. Opin. Obstet. Gynecol. 19, 395-401 (2007).
31. Montgomery GW, Nyholt DR, Zhao ZZ et al.: The search for genes contributing to endometriosis risk. Hum. Reprod. Update 14, 447-457 (2008).
32. Szklo M, Nieto FJ: Epidemiology: Beyond the Basics (2nd edition). Sudbury MA (Ed.). Jones and Bartlett Publishers, MA, USA (2007).
33. Porrello E, Monti MC, Sinforiani E et al.: Estrogen receptor a and APOEε4 polymorphisms interact to increase risk for sporadic AD in Italian females. Eur. J. Neurol. 13, 639-644 (2006).
34. Rocca WA, Grossardt BR, de Andrade M, Bower JH, Maraganore DM: Variants in genes in the estrogen synthesis and responsiveness pathway and risk of Parkinson's disease: a case-control study in women. Neurology 66, A64 (2006).
35. Luckhaus C, Sand PG: Estrogen receptor 1 gene (ESR1) variants in Alzheimer's disease. Results of a meta-ana lysis. Aging Clin. Exp. Res. 19, 165-168 (2007).
36. Maraganore DM, de Andrade M, Lesnick TG et al.: High-resolution whole-genome association study of Parkinson disease. Am. J. Hum. Genet. 77, 685-693 (2005).
37. Hogervorst E, Bandelow S: Should surgical menopausal women be treated with estrogens to decrease the risk of dementia? Neurology 69, 1070-1071 (2007).
38. Yaffe K, Sawaya G, Lieberburg I, Grady D: Estrogen therapy in postmenopausal women: effects on cognitive function and dementia. JAMA 279, 688-695 (1998).
39. Hogervorst E, Williams J, Budge M, Riedel W, Jolles J: The nature of the effect of female gonadal hormone replacement therapy on cognitive function in post-menopausal women: a meta-ana lysis. Neuroscience 101, 485-512 (2000).
40. LeBlanc ES, Janowsky J, Chan BK, Nelson HD: Hormone replacement therapy and cognition: systematic review and meta-ana lysis. JAMA 285, 1489-1499 (2001).
41. Grodstein F, Clarkson TB, Manson JE: Understanding the divergent data on postmenopausal hormone therapy. N. Engl. J. Med. 348, 645-650 (2003).
42. Harman SM, Naftolin F, Brinton EA, Judelson DR: Is the estrogen controversy over? Deconstructing the Women's Health Initiative study: a critical evaluation of the evidence. Ann. NY Acad. Sci. 1052, 43-56 (2005).
43. Shumaker SA, Legault C, Rapp SR et al.: Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women: the Women's Health Initiative Memory Study: a randomized controlled trial. JAMA 289, 2651-2662 (2003).
44. Rapp SR, Espeland MA, Shumaker SA et al.: Effect of estrogen plus progestin on global cognitive function in postmenopausal women: the Women's Health Initiative Memory Study: a randomized controlled trial JAMA 289, 2663-2672 (2003).
45. Espeland MA, Rapp SR, Shumaker SA et al.: Conjugated equine estrogens and global cognitive function in postmenopausal women: Women's Health Initiative Memory Study. JAMA 291, 2959-2968 (2004).
46. Shumaker SA, Legault C, Kuller L et al.: Conjugated equine estrogens and incidence of probable dementia and mild cognitive impairment in postmenopausal women: Women's Health Initiative Memory Study. JAMA 291, 2947-2958 (2004).
47. Manson JE, Bassuk SS, Harman SM et al.: Postmenopausal hormone therapy: new questions and the case for new clinical trials. Menopause 13, 139-147 (2006).
48. Siegfried T: Neuroscience: it's all in the timing. Nature 445, 359-361 (2007).
49. Henderson VW, Benke KS, Green RC, Cupples LA, Farrer LA: Postmenopausal hormone therapy and Alzheimer's disease risk: interaction with age. J. Neurol. Neurosurg. Psychiatry 76, 103-105 (2005).
50. Barrett-Connor E: Hormones and heart disease in women: the timing hypothesis. Am. J. Epidemiol. 166, 506-510 (2007).
51. Wierman ME, Basson R, Davis S et al.: Androgen therapy in women: an Endocrine Society Clinical Practice guideline. J. Clin. Endocrinol. Metab. 91, 3697-3710 (2006).
52. Yaffe K, Barnes D, Lindquist K et al.: Endogenous sex hormone levels and risk of cognitive decline in an older biracial cohort. Neurobiol. Aging 28, 171-178 (2007).
53. Xu H, Gouras GK, Greenfield JP et al.: Estrogen reduces neuronal generation of Alzheimer β-amyloid peptides. Nat. Med. 4, 447-451 (1998).
54. Huang J, Guan H, Booze RM, Eckman CB, Hersh LB: Estrogen regulates neprilysin activity in rat brain. Neurosci. Lett. 367, 85-87 (2004).
55. Casadesus G, Milliken EL, Webber KM et al.: Increases in luteinizing hormone are associated with declines in cognitive performance. Mol. Cell. Endocrinol. 269, 107-111 (2007).
56. Rodrigues MA, Verdile G, Foster JK et al.: Gonadotropins and cognition in older women. J. Alzheimers Dis. 13, 267-274 (2008).
57. Casadesus G, Webber KM, Atwood CS et al.: Luteinizing hormone modulates cognition and amyloid-β deposition in Alzheimer APP transgenic mice. Biochim. Biophys. Acta 1762, 447-452 (2006).
58. Farrer LA, Cupples LA, Haines JL et al.: Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. A meta-analysis. APOE and Alzheimer Disease Meta Analysis Consortium. JAMA 278, 1349-1356 (1997).
59. Jorm AF, Mather KA, Butterworth P, Anstey KJ, Christensen H, Easteal S: APOE genotype and cognitive functioning in a large age-stratified population sample. Neuropsychology 21, 1-8 (2007).
60. Cheng X, McAsey ME, Li M et al.: Estradiol replacement increases the low-density lipoprotein receptor related protein (LRP) in the mouse brain. Neurosci. Lett. 417, 50-54 (2007).
61. Struble RG, Cady C, Nathan BP, McAsey M: Apolipoprotein E may be a critical factor in hormone therapy neuroprotection. Front. Biosci. 13, 5387-5405 (2008).
62. Stone DJ, Rozovsky I, Morgan TE, Anderson CP, Finch CE: Increased synaptic sprouting in response to estrogen via an apolipoprotein E-dependent mechanism: implications for Alzheimer's disease. J. Neurosci. 18, 3180-3185 (1998).
63. Horsburgh K, Macrae IM, Carswell H: Estrogen is neuroprotective via an apolipoprotein E-dependent mechanism in a mouse model of global ischemia. J. Cereb. Blood Flow Metab. 22, 1189-1195 (2002).
64. Nathan BP, Barsukova AG, Shen F, McAsey M, Struble RG: Estrogen facilitates neurite extension via apolipoprotein E in cultured adult mouse cortical neurons. Endocrinology 145, 3065-3073 (2004).
65. Mattila KM, Axelman K, Rinne JO et al.: Interaction between estrogen receptor 1 and the ε4 allele of apolipoprotein E increases the risk of familial Alzheimer's disease in women. Neurosci. Lett. 282, 45-48 (2000).
66. Yaffe K, Haan M, Byers A, Tangen C, Kuller L: Estrogen use, APOE, and cognitive decline: evidence of gene-environment interaction. Neurology 54, 1949-1954 (2000).
67. Burkhardt MS, Foster JK, Laws SM et al.: Oestrogen replacement therapy may improve memory functioning in the absence of APOE ε4. J. Alzheimers Dis. 6, 221-228 (2004).
68. Rippon GA, Tang MX, Lee JH, Lantigua R, Medrano M, Mayeux R: Familial Alzheimer disease in Latinos: interaction between APOE, stroke, and estrogen replacement. Neurology 66, 35-40 (2006).
69. Kanehisa M, Goto S, Hattori M et al.: From genomics to chemical genomics: new developments in KEGG. Nucleic Acids Res. 34, D354-D357 (2006).
70. Hanson MA, Gluckman PD: Developmental origins of health and disease: new insights. Basic Clin. Pharmacol. Toxicol. 102, 90-93 (2008).
71. Grandjean P: Late insights into early origins 71. of disease. Basic Clin. Pharmacol. Toxicol. 102, 94-99 (2008).
72. Day JC: Population projections of the United States, by age, sex, race, and Hispanic origin: 1993 to 2050. Current population reports, US Government Printing Office, Washington, DC, 25-1104 (1993).
73. Wimo A, Jonsson L, Winblad B: An estimate of the worldwide prevalence and direct costs of dementia in 2003. Dement. Geriatr. Cogn. Disord. 21, 175-181 (2006).
74. Brookmeyer R, Johnson E, Ziegler-Graham K, Arrighi HM: Forecasting the global burden of Alzheimer's disease. Alzheimers Dement. 3, 186-191 (2007).
75. Rocca WA: Dementia, Parkinson's disease, and stroke in Europe: a commentary. Neurology 54, S38-S40 (2000).
76. Fratiglioni L, Rocca WA: Epidemiology of dementia. In: Handbook of Neuropsychology. Boller F, Cappa S (Eds). Elsevier, Amsterdam, The Netherlands 193-215 (2001).